Global Ophthalmics Partnering 2016-2023: Deal trends, players and financials

No Publisher
WILD10986
$3,995.00

Global Ophthalmics Partnering 2016 to 2023 provides the full collection of ophthalmics disease deals signed between the world’s pharmaceutical and biotechnology companies since 2016.

Trends in ophthalmics partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Ophthalmics partnering agreement structure
Ophthalmics partnering contract documents
Top ophthalmics deals by value
Most active ophthalmics dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive ophthalmics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering ophthalmics deals.

The report presents financial deal terms values for ophthalmics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of ophthalmics dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in ophthalmics dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading ophthalmics deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active Ophthalmics dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to ophthalmics deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all ophthalmics partnering deals by specific Ophthalmics target announced since 2016. The chapter is organized by specific ophthalmics therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all ophthalmics partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in ophthalmics partnering and dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of ophthalmics technologies and products.

Report scope

Global Ophthalmics Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to ophthalmics trends and structure of deals entered into by leading companies worldwide.

Global Ophthalmics Partnering 2016 to 2023 includes:

Trends in ophthalmics dealmaking in the biopharma industry since 2016
Access to headline, upfront, milestone and royalty data
Access to hundreds of ophthalmics deal contract documents
Comprehensive access to over 600 ophthalmics deal records
The leading ophthalmics deals by value since 2016
Most active ophthalmics dealmakers since 2016

The report includes deals for the following indications: Age-related macular degeneration, Blindness, Cataracts, Conjunctivitis, Diabetic macular edema, Dry eye, Glaucoma, Ocular hypertension, Retinal detachment Retinopathy, Diabetic retinopathy, Uveitis, plus other ophthalmic indications.

In Global Ophthalmics Partnering 2016 to 2023, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Ophthalmics Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 600 ophthalmics deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

'

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in ophthalmics dealmaking

2.1. Introduction
2.2. Ophthalmics partnering over the years
2.3. Ophthalmics partnering by deal type
2.4. Ophthalmics partnering by industry sector
2.5. Ophthalmics partnering by stage of development
2.6. Ophthalmics partnering by technology type
2.7. Ophthalmics partnering by therapeutic indication

Chapter 3 –Financial deal terms for ophthalmics partnering

3.1. Introduction
3.2. Disclosed financials terms for ophthalmics partnering
3.3. Ophthalmics partnering headline values
3.4. Ophthalmics deal upfront payments
3.5. Ophthalmics deal milestone payments
3.6. Ophthalmics royalty rates

Chapter 4 – Leading ophthalmics deals and dealmakers

4.1. Introduction
4.2. Most active in ophthalmics partnering
4.3. List of most active dealmakers in ophthalmics
4.4. Top ophthalmics deals by value

Chapter 5 – Ophthalmics contract document directory

5.1. Introduction
5.2. Ophthalmics partnering deals where contract document available

Chapter 6 – Ophthalmics dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by ophthalmics therapeutic target

Appendices

Appendix 1 – Directory of ophthalmics deals by company A-Z 2016 to 2023
Appendix 2 – Directory of ophthalmics deals by deal type 2016 to 2023
Appendix 3 – Directory of ophthalmics deals by stage of development 2016 to 2023
Appendix 4 – Directory of ophthalmics deals by technology type 2016 to 2023
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

Table of figures

Figure 1: Ophthalmics partnering since 2016
Figure 2: Ophthalmics partnering by deal type since 2016
Figure 3: Ophthalmics partnering by industry sector since 2016
Figure 4: Ophthalmics partnering by stage of development since 2016
Figure 5: Ophthalmics partnering by technology type since 2016
Figure 6: Ophthalmics partnering by indication since 2016
Figure 7: Ophthalmics deals with a headline value
Figure 8: Ophthalmics deals with upfront payment values
Figure 9: Ophthalmics deals with milestone payment
Figure 10: Ophthalmics deals with royalty rates
Figure 11: Active ophthalmics dealmaking activity– 2016 to 2023
Figure 12: Top ophthalmics deals by value since 2016

3D-Micromac, 3M, 3SBio, 4D Molecular Therapeutics, 4P-Pharma, A*STAR Agency for Science, Technology and Research, AAVnerGene, ABB Optical Group, Abbott Medical Optics, Abbvie, AbCellera Biologics, ABL Bio, Abpro, Abzena, AccelMed, Accure Therapeutics, ACE Solutech, Achillion Pharmaceuticals, ActiveSite, ActualEyes, Acucela, AcuFocus, Adaptive Phage Therapeutics, Adtech Pharma, Advanced Tear Diagnostics, Adverum Biotechnologies, Aequus Pharmaceuticals, Aerie Pharmaceuticals, AffaMed Therapeutics, Affilogic, AFT Pharmaceuticals, AGC Biologics, Aier Eye Hospital Group, AimMax Therapeutics, AiVita Biomedical, AJU Pharma, Aker BioMarine, Akorn, Alcon Laboratories, Aldevron, Alexion Pharmaceuticals, Alfa Instruments, Alienware, Alimera Sciences, Allegro Ophthalmics, Allergan, Allotex, Alloy Therapeutics, Alnylam Pharmaceuticals, ALS Association, Altus Formulation, Alvotech, Ambiopharm, Amblyotech, American Academy of Ophthalmology, American Diabetes Association, AmerisourceBergen, Amneal Pharmaceuticals, AmorChem, Amydis, Andrec, AnGes MG, Angios, Annapurna Therapeutics, AntriaBio, Apellis Pharmaceuticals, Apexian Pharmaceuticals, Applied Genetic Technologies, Apposite Capital, Aptar Pharma, Arctic Therapeutics, Arctic Vision, Arctos Medical, Argentum Pharmaceuticals, Ascendia Pharmaceuticals, Asian Eye Institute, ASICO, Astellas Pharma, Attillaps Holdings, Aura Biosciences, Aurinia Pharmaceuticals, Auven Therapeutics, Avalanche Biotechnologies, Avanzanite Bioscience, Avellino Labs, Avista Therapeutics, Avizorex Pharma, Avulux, Axantia, AXIM Biotechnologies, Axon Optics, AyoxxA Biosystems, Azura Ophthalmics, Baker Brothers Investments, BalGeunSeSang Eye Clinic, Barron Precision Instruments, Bascom Palmer Eye Institute, Bausch & Lomb, Bausch Health Companies, Baxalta, Baxter International, Bayer, Beam Therapeutics, Benz Research & Development, Betaliq, Beta Therapeutics, Betta Pharmaceuticals, Beyeonics Vision, BHVI, Bio-Techne, Bio-Tissue, Bioeq IP, Biogen, BioInvent, BioLamina, BiolineRX, Bionic Sight, Blackrock Neurotech, BLP Management, Bluejay Diagnostics, Blueprint Genetics, BlueRock Therapeutics, Boehringer Ingelheim, BostonSight, Breckenridge Pharmaceuticals, BridgeBio Pharma, Bridge Biotherapeutics, Brigham and Women's Hospital, BrightFocus Foundation, Bright Optical, Brill Pharma, Broadwing Bio, BVI Medical, C-Bridge Capital, Calcimedica, California Institute for Regenerative Medicine, Cambridge Research Biochemicals, Cannabics Pharmaceuticals, Capsida Biotherapeutics, Carl Zeiss Meditec, Casebia Therapeutics, Case Western Reserve University, Castle Biosciences, Catalent, Catalyst Biosciences, CDR-Life, Celanese, Cella Therapeutics, Cell Care Therapeutics, Cell Cure Neurosciences, Cellular Dynamics International, Cellusion, Celregen, Center for Breakthrough Medicines, Cerevast Therapeutics, Changchun High & New Technology Industries, Charles River Laboratories, Chiesi Farmaceutici, Children's Hospital Los Angeles, Children's Medical Research Institute, China Grand Pharmaceutical, China Medical System, China Pharma Holdings, Cipla, CiRC Biosciences, Clarion Medical Technologies, ClearPoint Neuro, Clearside Biomedical, Clinical Edge, Clover Therapeutics, Coave Therapeutics, Coherus Biosciences, Columbia Technology Ventures, Columbia University, Combangio, Commonwealth of Pennsylvania, Compact Imaging, Consort Medical, Contamac, Cooper-Vemedia, Cooper Companies, Copernicus Therapeutics, Corneal Lens, Corning, Cortigent, Corza Medical, Covenant Surgical Partners, CrestOptics, CRISPR Therapeutics, CROMA Pharma, CS Pharmaceuticals, Curacle, CUREator, CureVac, Cyagen Biosciences, Cyclica, D. Western Therapeutics Institute, Daiichi Sankyo, Dallas Lighthouse for the Blind, De La Pena Eye Clinic, DelSiTech, Department of Defense, Department of Veterans Affairs, Dermira, Diagnos, Diamond Pharma Services, Diana Davis Spencer Foundation, Digital Diagnostics, Diopsys, DNA/GPS, DNX Biopharmaceuticals, doc.ai, Dompe Farmaceutici, DOSE Medical, DotBio, Dr. Agarwal’s Eye Hospitals, Dr. Reddy's Laboratories, DRI Capital, DryEye Rescue, DSM, Duke-NUS Graduate Medical School Singapore, Duke University, Dyno Therapeutics, Eagle Vision, Eastman Chemical Company, ECMOHO, Editas Medicine, EKKDA Research, Elektron Eye Technology, Eleven Biotherapeutics, ElsaLys Biotech, ELT Sight, Eluminex Biosciences, EMC, Emmes, Encore Vision, Envisia Therapeutics, Epimune Diagnostics, Equinox Science, eSight, Essex Bio-Technology, Essilor, ESW Vision, Eton Pharmaceuticals, Everads Therapy, Evergaze, Eversana, Eversight, Evommune, Evotec, Ewopharma, Exonate, EyeCare Services Partners, EyeCRO, Eyedea Medical, Eyeganics, Eyegate Pharmaceuticals, EyeMedics, Eyenovia, Eyeon Therapeutics, EyePoint Pharmaceuticals, EyeQ Vision, EyeTracking, Eyevance, Eyevensys, Famy Life Sciences, FarmaMondo Group, Fibrogen, Find Therapeutics, First Insight, Flexpoint Sensor Systems, Florida Pharmaceutical Products, Focal, Focus Laboratories, Forge Biologics, Formosa Pharmaceuticals, ForSight VISION4, ForSight VISION5, Fortify Therapeutics, Fortress Biotech, Foundation Fighting Blindness, FS Development, FUJIFILM Cellular Dynamics, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, Galapagos, Galimedix Therapeutics, GAMUT Therapeutics, Garuda Health Services, Gauss Surgical, Gelest, Gemini Therapeutics, Genentech, Genosity, Gensight Biologics, Gentex, Gestion Univalor, GHO Capital, Gilead Sciences, Glaucoma Research Foundation, Glaukos, Glenmark Pharmaceuticals, GrayBug Vision, Grifols, Gyroscope Therapeutics, Halozyme Therapeutics, HanAll Pharmaceuticals, Harbour Biomed, Harrow Health, Harvard Medical School, HealPros, Healthcare Royalty Partners, Healthe Care Australia, Heidelberg Engineering, Helvetic Biopharma, Hemera Biosciences, Hemostemix, Hitachi Chemical, Homology Medicines, Hopstem Biotechnology, Horama, Horizon Discovery, Horizon Europe, Horizon Pharma plc, Horizon Therapeutics, Horus Pharma, Hovione, Howard Foundation, HOYA Vision Care, HPGC Medical, I-MED Pharma, IACTA Pharmaceuticals, IBM, Ichor Life Sciences, Iconic Therapeutics, IDx, Immervision, Imprimis Pharmaceuticals, ImprimisRx, Indoco, Industrial Technology Research Institute, Inflammasome Therapeutics, InformedDNA, InMed Pharmaceuticals, InnFocus, Innovia Medical, Inserm Transfert, Intas Pharmaceuticals, Intellia Therapeutics, Intratus, Iogen, Ionis Pharmaceuticals, iOR Partners, IQVIA, Iridex, IRIS, IRIS International, Iris Pharma, IrisVision, Israeli National Authority for Technological Innovation, iSTAR Medical, Itrom Pharmaceutical Group, Ivantis, iVeena delivery Systems, Iveric Bio, Jackson Laboratory, Jade Therapeutics, Jaeb Center for Health Research Foundation, Janssen Pharmaceuticals, Janssen Research & Development, jCyte, Ji Xing Pharmaceuticals, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Johnson & Johnson Vision, Joslin Diabetes Center, Kala Pharmaceuticals, Kali Care, KalVista Pharmaceuticals, Kanaph Therapeutics, Katena Products, KC Pharmaceuticals, Kedalion Therapeutics, Keen Eye, Kemwell BioPharma, Klinge Biopharma, Kobe Kanagawa Eye Clinic, Kochoptik, Kodiak Sciences, Konkuk University, Kriya Therapeutics, Kubota Pharmaceutical, Kubota Vision, Kuria Therapeutics, Laboratoires Thea, Lacrimedics, LambdaVision, Lansheng Medical, Lantheus Holding, Launch Therapeutics, Lee's Pharmaceutical, Leica Microsystems, Leiden University, Leidos, Leiters, LensAR, LENZ Therapeutics, LGC, LianBio, Lin Bioscience, Lineage Cell Therapeutics, LION Eye Group, LLamasoft, Lochan, Lonza, Lubris BioPharma, LumiThera, Lund University, LV Prasad Eye Institute, mAbXience, MacuHealth, MacuLogix, Mannin Research, Marathon Medical, Marchon Eyewear, Massachusetts Eye and Ear Infirmary, Mawson Infrastructure, Mayo Clinic, Maze Therapeutics, McMaster University, mCureX Therapeutics, Mectizan Donation Program, Medical Food Solutions Research, Medical Research Foundation, Medical University of South Carolina, Mediconsult.com, MedImmune, MeiraGTx, MellingMedical, Memira Holding, Menicon, Merck and Co, Merck Animal Health, Merz, Meyer Children's Hospital of Florence, Micro-Select Instruments, Miloftalmica, Minaris Regenerative Medicine, MiniFab, Minnetronix, miRagen Therapeutics, MitoChem Therapeutics, Mitsubishi Tanabe Pharma, MLase, Mobius Therapeutics, MolMed, Mosaic Biosciences, Mperia Therapeutics, MPI Research, Mundipharma, Mylan Pharmaceuticals, MyMD Pharmaceuticals, Nacuity Pharmaceuticals, Nanoform, Nanomerics, Nanoscope Therapeutics, NanoViricides, Narayana Nethralaya Foundation, NASA, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Eye Institute, National Healthcare Services (NHS), National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institutes of Health, National Organization for Rare Disorders, National Science Foundation, National University of Singapore, NEMUS Bioscience, Neuraly, Neurolens, Neurophth Therapeutics, NeuroVive Pharmaceutical, Nevakar, Newport Research, NextPharma, NGM Biopharmaceuticals, Nicox, Nightstar Therapeutics, NKL, Nordic Prime, Northway Biotechpharma, Notal Vision, NovaBay Pharmaceuticals, Novaliq, Novartis, Noveome Biotherapeutics, Novo Nordisk, Novotech, NTC, NuEyes, Numab, NuSight Medical, Ocugen, Ocular Technologies, Ocular Therapeutics, Ocular Therapeutix, Oculis, Oculogenex, OcuMedic, Ocumension Therapeutics, OcuNexus Therapeutics, Ocuphire Pharma, OCuSOFT, Odylia Therapeutics, Ohr Pharmaceuticals, OKKO Health, Okra, OKYO Pharma, OliX Pharmaceuticals, Olympic Ophthalmics, Omega Therapeutics, Omeros, OmniVision Technologies, ONL Therapeutics, OphtAI, Ophthotech, Opsis Therapeutics, Opthea, Optibrand, Optifye Therapeutics, OptiKira, Optima Pharmazeutische, Optina Diagnostics, Optomed, Optometric Extension Program Foundation, Optos, Optovue, Opus Genetics, Ora, Orbis, Orbit Biomedical, OrCam, Oregon Health Sciences University, Oregon National Primate Research Center, Orsini Healthcare Specialty Pharmacy, Osmotica Pharmaceuticals, Osterhout Design Group, Outlook Therapeutics, Oxford BioMedica, Oxurion, Oyster Point Pharma, Panoptes Pharma, PanOptica, Paragon Biosciences, Paragon Care Group, Par Pharmaceutical, PeptiDream, Perelman School of Medicine, Performance Optics, PharmAbcine, Pharmaleads, Phillips-Medisize, Pieris Pharmaceuticals, Pierre Fabre, Ping An Ventures, Pixium Vision, Plex Pharmaceuticals, PolyPhotonix, PreCerv, Preceyes, Precise Biometrics, Precision Eye Services, Precision Lens, Precision Ocular, Precision Optics, Prevail InfoWorks, Promedica International, ProQR Therapeutics, ProtoKinetix, Provet, pSivida, PTC Therapeutics, Q BioMed, Queensland University of Technology, Quest Diagnostics, Quidel, Quotient, Rallybio, Rayner Surgical, Ray Therapeutics, RecensMedical, Recordati, Regeneron Pharmaceuticals, Regenerx, ReGenTree, Regenxbio, Remidio Innovative Solutions, Research to Prevent Blindness, Resilience, Retinagenix, RetinAI Medical, Retina Institute, RetinalGeniX Technologies, RetroSense Therapeutics, ReVision Optics, Revision Skincare, Revolo Biotherapeutics, Rexahn Pharmaceuticals, Ribomic, RightEye, Ripple Therapeutics, River Vision Development, Roche, ROCOL, Rotterdam Eye Hospital, RVL Pharmaceuticals, RxCell, RxEye, Saban Research Institute of Children's Hospital Los Angeles, Sam Chun Dang Pharm, Samsara Vision, Samsung Bioepis, Samsung Biologics, Samsung Electronics, SanBio, Sanoculis, Sanofi, Santen, Santen Pharmaceutical, Santhera Pharmaceuticals, Saphetor, SATT Conectus Alsace, SBI Capital Markets, Schepens Eye Research Institute, Scohia Pharma, Second Sight Medical, Sectra, Selagine, SemaThera, Senju Pharmaceutical, Senshinkai Eye Institute, Sensor Medical Technology, Senti Biosciences, Sentrx, Shandong Boan Biological Technology, Shinagawa LASIK Centers, Shire Pharmaceuticals, SIFI (Societa Industria Farmaceutica Italiana), Sigenics, SightGlass Vision, SightLife Surgical, Sight Sciences, Singapore Eye Research Institute (SERI), Singapore National Eye Centre, Sintetica, SipNose, SiSaf, Skye Bioscience, Slayback Pharma, Smile Eyes Group, Sonoma Pharmaceuticals, SparingVision, Spark Therapeutics, Staar Surgical Co, STADA Arzneimittel, Stanford University, Stanford University School of Medicine, State University of New York, Streetlab, Stuart Therapeutics, Sun Pharmaceutical, Surrozen, SwissLens, SWK Funding, Sydnexis, Syncona Partners, SynergEyes, Taiwan Liposome Company, Takeda Pharmaceutical, TALLC, Tamid Bio, Tangible Science, Tanner Pharmaceuticals, Taro Pharmaceuticals, Tarsius Pharma, Tarsus Pharmaceuticals, TeamedOn International, TearLab, TearScience, Technological University Dublin, Teijin, Teleon Surgical, Tetra Bio-Pharma, Teva Pharmaceutical Industries, Thea Open Innovation, Therakine, The Regents of the University of California, ThinkCyte, ThromboGenics, Tianjin CanSino Biotechnology, Tilak Healthcare, Titan Pharmaceuticals, Tobii Technology, Toolgen, Topcon, TOT BIOPHARM, Transcend Medical, Transitions Optical, Translational Research Institute for Space Health, Translatum Medicus, Trefoil Therapeutics, Trethera, TRIGR Therapeutics, Tu Dresden, Tufts Medical Center, Tufts University, twoXAR, U.S. First Responders Association, UCB, Ulster University, Uni-Bio Science, University College London, University of British Columbia, University of California, University of California, San Diego, University of California Los Angeles, University of California San Francisco, University of Cologne, University of Colorado, University of Florida, University of Florida Research Foundation, University of Hong Kong, University of Illinois at Chicago, University of Massachusetts, University of Massachusetts Medical School, University of Minnesota, University of Nebraska, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh, University of Pittsburgh Medical Center, University of Utah, University of Washington, University Paris Diderot, Upsher-Smith, US Army, Usher III, Usher Syndrome Coalition, US Vision, Valeant Pharmaceuticals, ValenzaBio, Vanda Pharmaceuticals, Vasomune Therapeutics, Vedere Bio, Verana Health, Versant Health, Versea Ophthalmics, Vial, Viatris, Viela Bio, ViewPoint Therapeutics, ViGeneron, Viridian Therapeutics, VISIA Imaging, Vision Care Group, VisionCare Ophthalmic Technologies, Visioneering Technologies, Vision Essence, Vision Institute, VisionQuest Biomedical, VisionWeb, Vista Oftalmólogos, Visus Therapeutics, Vitrisa Therapeutics, Vivani Medical, VivaVision Biotech, Vivior, Vizient, Volk Optical, Voxtur, VSP Optics, Vyluma, Wagner Macula Retina Center, Wakamoto Pharmaceutical, Wake Forest University, Wallace H. Coulter Foundation, Wellcome Trust, Wellspring Ophthalmics, World Eye Hospital, WuXi Advanced Therapies, Xbrane Bioscience, Xencor, XERIS Pharmaceuticals, XL-Protein, Yangtze River Pharmaceutical Group, YouHealth Eyetech, Zebra Medical Vision, Zhaoke (Hong Kong) Ophthalmology Pharmaceutical, Zhonglan Electronic Technology, Zizhu Pharma

$3,995.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838